SENSEX    39140.28       -135.36    |    NIFTY    11752.8       -34.35 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Eris Lifesciences gains after loan pre-payment
15-Apr-19   14:04 Hrs IST

The announcement was made after market hours on Friday, 12 April 2019.

Meanwhile, the S&P BSE Sensex was up 157.10 points or 0.41% at 38,924.21

On the BSE, 500 shares were traded on the counter so far as against the average daily volumes of 6,160 shares in the past two weeks. The stock had hit a high of Rs 643.75 and a low of Rs 638 so far during the day.

Eris Lifesciences notified that the company has pre-paid the entire loan facility obtained from Axis Bank (Lender). The loan facility agreements dated 30 November 2017 with Axis Bank Limited therefore stand closed / terminated, it added.

On a consolidated basis, net profit of Eris Lifesciences rose 7.05% to Rs 80.20 crore on 19.74% rise in net sales to Rs 248.48 crore in Q3 December 2018 over Q3 December 2017.

Eris Lifesciences is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti-diabetes; vitamins; gastroenterology and gynaecology.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.87 78.51 1.13
United Kingdom (GBP) 1.15 1.00 90.63 1.30
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.88 0.77 69.47 1.00
Commodities << ALL Commodities
GOLDAHMD31394-247
SILVERAHMD3719111
CRUDEOILMUMBAI4436-20
COPPERMUMBAI455.25.70
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INB010982739   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2008 certified)